Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin Treatment in Patients With Liver Cirrhosis: A Retrospective Cohort Study

Ähnliche Einträge

• Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study
  von: Satoru Kakizaki, et al.
  Veröffentlicht: (2026)
• Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis
  von: Takao Miwa, et al.
  Veröffentlicht: (2025)
• Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
  von: Tsutomu Nishida, et al.
  Veröffentlicht: (2025)
• Letter to the Editor: “Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis”
  von: Yumin Guo, et al.
  Veröffentlicht: (2025)
• Animal Naming Test Can Identify Covert Hepatic Encephalopathy in Patients With Cirrhosis With Limited Influence From Age or Educational Level
  von: Takao Miwa, et al.
  Veröffentlicht: (2025)